---
title: "Cue grants RSUs to CEO Shao-Lee Lin, CLO Sumita Ray and PAO Michael Meluzio"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/292360224.md"
description: "Cue Biopharma granted 1,064,492 restricted stock units (RSUs) on July 9, 2026, to executives and officers under its 2026 Stock Incentive Plan. CEO Shao-Lee Lin received 655,074 RSUs, CLO Sumita Ray received 109,178, PAO Michael Meluzio received 81,884, and each non-employee director received 21,800 RSUs."
datetime: "2026-07-10T21:33:00.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/292360224.md)
  - [en](https://longbridge.com/en/news/292360224.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/292360224.md)
generator: "portal-rs"
---

# Cue grants RSUs to CEO Shao-Lee Lin, CLO Sumita Ray and PAO Michael Meluzio

**Cue granted a total of 1,064,492 restricted stock units to employees and officers on July 9, 2026, including awards to President and CEO Shao-Lee Lin, Chief Legal and Compliance Officer Sumita Ray, and Principal Accounting Officer Michael Meluzio.**

**Individual**

Shao-Lee Lin

Sumita Ray

Michael Meluzio

Non-employee directors (each)

**Role**

President and Chief Executive Officer

Chief Legal and Compliance Officer and Corporate Secretary

Principal Accounting Officer

Director

**Type of Change**

Equity award granted

Equity award granted

Equity award granted

Equity award granted

**Effective Date**

July 9, 2026

July 9, 2026

July 9, 2026

July 9, 2026

**Reason**

To implement 2026 Stock Incentive Plan / long-term incentive framework

To implement 2026 Stock Incentive Plan / long-term incentive framework

To implement 2026 Stock Incentive Plan / long-term incentive framework

To implement 2026 Stock Incentive Plan / long-term incentive framework

**Replacement Info**

Not disclosed

Not disclosed

Not disclosed

Not disclosed

**Background Details**

Received award of 655,074 RSUs

Received award of 109,178 RSUs

Received award of 81,884 RSUs

Each received 21,800 RSUs

**Board/Committee Role Changes**

Not disclosed

Not disclosed

Not disclosed

Not disclosed

Original SEC Filing: Cue Biopharma, Inc. \[ CUE \] - 8-K - Jul. 10, 2026

**Disclaimer**

This is an AI-powered summary. It may contain inaccuracies. Consider verifying important information with the source. Please note this summary is solely based on documents filed with the SEC.

### Related Stocks

- [CUE.US](https://longbridge.com/en/quote/CUE.US.md)

## Related News & Research

- [Cue Biopharma Chief Executive Officer Sold Shares Worth Over $1.6M](https://longbridge.com/en/news/295986047.md)
- [Flexsteel Q4 2026 Earnings Preview](https://longbridge.com/en/news/296031749.md)
- [INVEST: Revenue and profit dropped sharply in H1 2026, with 2026 outlook remaining subdued](https://longbridge.com/en/news/296439091.md)
- [Algorhythm Holdings Reports Second Quarter 2026 Financial Results](https://longbridge.com/en/news/296124832.md)
- [Baker Hughes declares Q3 2026 dividend of R$ 0.81 per unit](https://longbridge.com/en/news/296392545.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**